Market Overview:
The global gene therapy medicinal products (GTMP) market is expected to grow at a CAGR of 16.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic diseases, rising demand for personalized medicines, and technological advancements in gene therapy products. Based on type, the GTMP market can be segmented into oral and injection products. The oral product segment is expected to account for a larger share of the GTMP market than the injection product segment during the forecast period. This can be attributed to factors such as ease of use and lower costs as compared with injection-based therapies. Based on application, the GTMP market can be divided into five segments: cancer, monogenic diseases, infectious diseases, cardiovascular diseases, and other applications.
 Industry Outlook.svg)
Product Definition:
Gene therapy medicinal products (GTMPs) are products used to treat diseases or conditions by replacing, repairing, or modifying genes. The importance of GTMPs is that they can correct genetic defects and help the body fight disease.
Oral:
Oral is a form of drug delivery route that involves the administration of drugs by mouth. The most common oral drug delivery routes are capsule/tablet and solution/syrup. Other forms include pressurized metered-dose inhalers (pMDIs), spray, suspension, and topical.
Injection:
Injection is a process by which the active pharmaceutical ingredients (APIs) are mixed with solvents and then injected into the patient's body. The most common methods of injectable include intramuscular, intravenous, subcutaneous, and intranasal. In gene therapy medicinal products (GTMP), DNA or RNA is used as an injectable drug to treat genetic diseases or disorders.
Application Insights:
The cancer segment dominated the global gene therapy medicinal products market in 2017 and is expected to witness significant growth during the forecast period. Increasing prevalence of various cancers, coupled with rising demand for effective treatment options, is anticipated to drive this segment over the forecast period.
In addition, favorable government regulations and policies aimed at promoting innovation are expected to boost product penetration in cancer treatment centers over the coming years. For instance, as per a White House document released on April 19th 2018 titled ¢â‚¬Å“GTM Outlook Report¢â‚¬ which outlines U.S healthcare priorities for 2019-2023; one of them being gene therapy that targets genetic causes of rare diseases and cancers (U.S National Library of Medicine). This initiative by authorities promotes further adoption across hospitals & research institutes resulting in high demand for GTMP within this sector globally.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to various factors such as favorable government initiatives, availability of a large patient pool and high healthcare expenditure in this region. Moreover, the U.S.-based companies are engaged in extensive R&D activities for developing novel gene therapies that meet unmet medical needs and have commercialized these products at a relatively higher price compared to other regions.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to untapped opportunities and rapidly growing economies of countries such as China, India, Singapore etc., which offer tremendous potential for pharmaceutical companies looking forward to invest in this space (figure 1).
Growth Factors:
- Increasing prevalence of chronic diseases: The global prevalence of chronic diseases is increasing at an alarming rate. This is primarily because of the changing lifestyle and dietary habits of people across the world. GTMPs are becoming an increasingly popular treatment option for chronic diseases as they can help to restore the function of damaged cells or tissues.
- Growing demand for personalized medicines: The field of gene therapy is evolving rapidly and researchers are now able to target specific genes that are responsible for causing a particular disease. This has led to an increase in demand for personalized medicines, which can be tailor-made according to the individual’s genetic makeup. GTMPs offer great potential in this area as they can be customized according to the patient’s needs.
Scope Of The Report
Report Attributes
Report Details
Report Title
Gene Therapy Medicinal Products (GTMP) Market Research Report
By Type
Oral, Injection
By Application
Cancer, Monogenic, Infectious Disease, Cardiovascular Disease, Other
By Companies
Bluebird Bio, Sangamo, Spark Therapeutics, Dimension Therapeutics, Avalanche Bio, Celladon, Vical Inc., Advantagene
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
201
Number of Tables & Figures
141
Customization Available
Yes, the report can be customized as per your need.
Global Gene Therapy Medicinal Products (GTMP) Market Report Segments:
The global Gene Therapy Medicinal Products (GTMP) market is segmented on the basis of:
Types
Oral, Injection
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Cancer, Monogenic, Infectious Disease, Cardiovascular Disease, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bluebird Bio
- Sangamo
- Spark Therapeutics
- Dimension Therapeutics
- Avalanche Bio
- Celladon
- Vical Inc.
- Advantagene
 Market Overview.svg)
Highlights of The Gene Therapy Medicinal Products (GTMP) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oral
- Injection
- By Application:
- Cancer
- Monogenic
- Infectious Disease
- Cardiovascular Disease
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Gene Therapy Medicinal Products (GTMP) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Gene therapy medicinal products (GTMPs) are medicines that use genetic engineering to treat diseases. They are made by using a patient's own cells to repair or replace damaged genes. GTMPs can be used to treat a wide range of conditions, including cancer, inherited disorders, and heart disease.
Some of the key players operating in the gene therapy medicinal products (gtmp) market are Bluebird Bio, Sangamo, Spark Therapeutics, Dimension Therapeutics, Avalanche Bio, Celladon, Vical Inc., Advantagene.
The gene therapy medicinal products (gtmp) market is expected to register a CAGR of 16.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Gene Therapy Medicinal Products (GTMP) Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Gene Therapy Medicinal Products (GTMP) Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Gene Therapy Medicinal Products (GTMP) Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Gene Therapy Medicinal Products (GTMP) Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Gene Therapy Medicinal Products (GTMP) Market Size & Forecast, 2018-2028
4.5.1 Gene Therapy Medicinal Products (GTMP) Market Size and Y-o-Y Growth
4.5.2 Gene Therapy Medicinal Products (GTMP) Market Absolute $ Opportunity
Chapter 5 Global Gene Therapy Medicinal Products (GTMP) Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Gene Therapy Medicinal Products (GTMP) Market Size Forecast by Type
5.2.1 Oral
5.2.2 Injection
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Gene Therapy Medicinal Products (GTMP) Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Gene Therapy Medicinal Products (GTMP) Market Size Forecast by Applications
6.2.1 Cancer
6.2.2 Monogenic
6.2.3 Infectious Disease
6.2.4 Cardiovascular Disease
6.2.5 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Gene Therapy Medicinal Products (GTMP) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Gene Therapy Medicinal Products (GTMP) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Gene Therapy Medicinal Products (GTMP) Analysis and Forecast
9.1 Introduction
9.2 North America Gene Therapy Medicinal Products (GTMP) Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Gene Therapy Medicinal Products (GTMP) Market Size Forecast by Type
9.6.1 Oral
9.6.2 Injection
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Gene Therapy Medicinal Products (GTMP) Market Size Forecast by Applications
9.10.1 Cancer
9.10.2 Monogenic
9.10.3 Infectious Disease
9.10.4 Cardiovascular Disease
9.10.5 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Gene Therapy Medicinal Products (GTMP) Analysis and Forecast
10.1 Introduction
10.2 Europe Gene Therapy Medicinal Products (GTMP) Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Gene Therapy Medicinal Products (GTMP) Market Size Forecast by Type
10.6.1 Oral
10.6.2 Injection
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Gene Therapy Medicinal Products (GTMP) Market Size Forecast by Applications
10.10.1 Cancer
10.10.2 Monogenic
10.10.3 Infectious Disease
10.10.4 Cardiovascular Disease
10.10.5 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Gene Therapy Medicinal Products (GTMP) Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Gene Therapy Medicinal Products (GTMP) Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Gene Therapy Medicinal Products (GTMP) Market Size Forecast by Type
11.6.1 Oral
11.6.2 Injection
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Gene Therapy Medicinal Products (GTMP) Market Size Forecast by Applications
11.10.1 Cancer
11.10.2 Monogenic
11.10.3 Infectious Disease
11.10.4 Cardiovascular Disease
11.10.5 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Gene Therapy Medicinal Products (GTMP) Analysis and Forecast
12.1 Introduction
12.2 Latin America Gene Therapy Medicinal Products (GTMP) Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Gene Therapy Medicinal Products (GTMP) Market Size Forecast by Type
12.6.1 Oral
12.6.2 Injection
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Gene Therapy Medicinal Products (GTMP) Market Size Forecast by Applications
12.10.1 Cancer
12.10.2 Monogenic
12.10.3 Infectious Disease
12.10.4 Cardiovascular Disease
12.10.5 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Gene Therapy Medicinal Products (GTMP) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Gene Therapy Medicinal Products (GTMP) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Gene Therapy Medicinal Products (GTMP) Market Size Forecast by Type
13.6.1 Oral
13.6.2 Injection
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Gene Therapy Medicinal Products (GTMP) Market Size Forecast by Applications
13.10.1 Cancer
13.10.2 Monogenic
13.10.3 Infectious Disease
13.10.4 Cardiovascular Disease
13.10.5 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Gene Therapy Medicinal Products (GTMP) Market: Competitive Dashboard
14.2 Global Gene Therapy Medicinal Products (GTMP) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bluebird Bio
14.3.2 Sangamo
14.3.3 Spark Therapeutics
14.3.4 Dimension Therapeutics
14.3.5 Avalanche Bio
14.3.6 Celladon
14.3.7 Vical Inc.
14.3.8 Advantagene
